Abstract:OBJECTIVE:To explore the clinical efficacy and adverse effects of GHA(G-CSF+homoharringtonin+cytarabine C) and new combined priming chemotherapeutic regimens(GHAA/GHTA) with high efficacy and low toxicity for treatment of relapsed and refractory acute myeloid leukemia(AML) and myelodysplastic syndrome(MDS), and to analyze the relation of above-mentioned regimens with the expression of co-stimuolating molecule B7.1.METHODS:Standard GHA regimen consisting of G-CSF: 100 µg/(m2·d) subcutaneous injection, d 0-14; homoharringtonine: 1.0 mg/(m2·d) intravenous drip, d 1-14; Ara-C: 7.5-10 mg/(m2·d) subcutaneous injection, q12h, d 1-14. Other regimens as GHAA/GHTA were combined respectively with aclarubicin 20 mg d 1-7, or pirarubicin 20 mg d 1-7. 74 patients with refractory AML and 46 patients with MDS received these priming chemotherapy. The clinical efficacy and toxicity of above-mentioned priming chemotherapy were compared with 56 patients received routine chemotherapy (MA/TAE) respectively. And the expression of costimulatory molecule B7.1 on leukemia cells in patients of different subtypes was also detected by immunofluoressence and its relationship with clinical efficiency was explored.RESULTS:(1) for AML patients treated with priming chemotherapy, the total remission was 67.56% (CR 54.05%, PR 13.51%), which was much higher than that of patients received routine chemotherapy (P<0.05). The CR rate of AML-M2 and AML-M5 group (65.51%, 61.90% respectively) was much higher than that of AML other subtypes (P<0.05), and the longest remission period lasted for 4 years; (2) for MDS patients treated with priming chemotherapy, the total remission was 60.87% (CR 45.65%, PR 15.22%), which was also significantly higher than that of patients received routine chemotherapy (P<0.05); (3) in comparison with patients received standard GHA priming regimen, the remission rate of combined priming chemotherapy GHAA/GHTA was significantly higher both in patients with AML (85.18%) and MDS (81.25%); (4) side effects after chemotheropy, including granulocyte deficiency, thrombocytopenia and anemia etc, lasted for 7-14 days; the severe infection rate was 1%, there were no severe bleeding, digest effect and damage of function in heart, liver and kidney. The therapy-related mortality was zero. Compared with routine chemotherapy, priming chemotherapy proved significantly safe and effective (P<0.05); (5) the expression rate of costimulatory molecule B7.1 showed large variance between AML and MDS, it was higher in AML-M2/AML-M5 and lower in AML of other subtypes (P<0.05). In the same case, B7.1 expression was positive correlated with efficiency of priming chemotherapy.CONCLUSION:GHA priming chemotherapy, as well as other combination regimens GHAA/GHTA, are well-tolerated, effective regimens for refractory AML and advanced MDS, without severe side effects and therapy-related mortality. Especially the new regimens GHAA/GHTA has better efficacy, which are proved more efficient than conventional GHA. Efficiency of priming chemotherapy is positive correlated with B7.1 expression, its mechanism will be further explored.

Are there any new insights for G-CSF and/or AMD3100 in chemotherapy of haematological malignants?

Mechanism of G-CSF and AMD3100 enhancing the chemotherapeutic sensitivity of leukemia cells

Effectiveness of AMD3100 in Treatment of Leukemia and Solid Tumors: from Original Discovery to Use in Current Clinical Practice

Modified Cladribine, Cytarabine, and G-CSF As a Salvage Regimen in Patients with Relapsed/refractory Acute Myeloid Leukemia: a Bridge to Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation

Preclinical Evaluation of Adjuvant Therapy with Amd3100 for Drug Resistant Philadelphia Chromosome Positive and Negative All

AMD3100 and G-CSF disrupt the cross-talk between leukemia cells and the endosteal niche and enhance their sensitivity to chemotherapeutic drugs in biomimetic polystyrene scaffolds

[Cohort Study on GHA and New Combined Priming Chemotherapeutic Regimens in Treatment of Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome].

GRANULOCYTE COLONY-STIMULATING FACTOR INHIBITS CXCR4/SDF-1A SIGNALING AND OVERCOMES STROMAL-MEDIATED DRUG RESISTANCE IN HL-60 CELL LINE

A Novel Bone Marrow Targeted Gadofullerene Agent Protect Against Oxidative Injury in Chemotherapy

Impact of Rhg-Csf on Clinical Efficacy and Immune Cell Subsets after Initial Induction Chemotherapy in AML

[Some Research Progress of CXCR4 Antagonist AMD3100].

Posttransplant Blockade of CXCR4 Improves Leukemia Complete Remission Rates and Donor Stem Cell Engraftment Without Aggravating GVHD.

Efficiency of GHA Priming Chemotherapy on Patients with Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome and Its Relation Ship with Expression of Costimulatory Molecule B7.1

Advances In Combination Of Antiangiogenic Agents Targeting Vegf-Binding And Conventional Chemotherapy And Radiation For Cancer Treatment

Associations of Granulocyte Colony-Stimulating Factor with Toxicities and Efficacy of Chimeric Antigen Receptor T-cell Therapy in Relapsed or Refractory Multiple Myeloma

Combination Chemotherapy with Low‐dose Cytarabine, Homoharringtonine, and Granulocyte Colony‐stimulating Factor Priming in Patients with Relapsed or Refractory Acute Myeloid Leukemia

Granulocyte Colony-Stimulating Factor Inhibits Cxcr4/Sdf-1 Signaling and Overcomes Stromal-Mediated Drug Resistance in Acute Myeloid Leukemia Via Mir-146a

Effect of Low-Dose Cytarabine, Homoharringtonine and Granulocyte Colony-Stimulating Factor Priming Regimen on Patients with Advanced Myelodysplastic Syndrome or Acute Myeloid Leukemia Transformed from Myelodysplastic Syndrome.

Selective Enhancement of Donor Hematopoietic Cell Engraftment by the CXCR4 Antagonist AMD3100 in a Mouse Transplantation Model

Old drug, new use: Recent advances for G-CSF

The Efficacy and Toxicity of the CHG Priming Regimen (Low-Dose Cytarabine, Homoharringtonine, and G-CSF) in Higher Risk MDS Patients Relapsed or Refractory to Decitabine